ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM, on Palliative Care for Patients With Hematologic Malignancies

Thomas W. LeBlanc, MD, of Duke University Medical Center, and Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, discuss the use of palliative and hospice care for patients with solid tumors vs hematologic cancers and clinicians’ attitudes (Abstracts e20554 and 9524).

Lymphoma

Andrew Zelenetz, MD, PhD

Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN

Andrew Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses two important lymphoma trials presented at ASCO and his views on whether their results are indeed practice-changing (Abstract 8504 and LBA8502).

Cost of Care

Leonard Saltz, MD

Leonard Saltz, MD, on Issues of Value in Melanoma Treatment

Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.

CNS Cancers

Jan C. Buckner, MD

Jan C. Buckner, MD, on Whole-Brain Radiation and Radiosurgery in Patients With Brain Metastases

Jan C. Buckner, MD, of the Mayo Clinic discusses adjuvant whole-brain radiotherapy and the need for initial treatment with radiosurgery and close monitoring to preserve cognitive function in patients with brain metastases (Abstract LBA4).

Global Cancer Care

Health-Care Policy

Lawrence N. Shulman, MD and Clifford A. Hudis, MD

Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss the delivery of cancer care in resource-constrained settings such as Rwanda and Haiti, and plans to conduct research in basic tumor biology of patients in these areas.

Aug

Today In Oncology

INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM, on Palliative Care for Patients With Hematologic Malignancies

Andrew Zelenetz, MD, PhD's Expert Analysis of Two Key Lymphoma Trials: FLASH and GADOLIN

Leonard Saltz, MD, on Issues of Value in Melanoma Treatment

Jan C. Buckner, MD, on Whole-Brain Radiation and Radiosurgery in Patients With Brain Metastases

Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

Outreach to HCT Recipients, Primary Care Doctors May Reduce Skin Cancer Risk

Navigating Early Relapse in Multiple Myeloma: New Evidence from the 2026 ASCO and EHA Congresses

FDA Seeks Public Input Relating to Regulatory Considerations for Generative AI–Enabled Medical Devices

Pilots and Flight Attendants Show Elevated Radiation-Related Cancer Mortality

INTerpath-001 Trial of mRNA-Based Individualized Neoantigen Therapy Meets Primary and Key Secondary Endpoints in Patients With High-Risk Resected Melanoma